Literature DB >> 27407025

Long-term outcome and its predictors in giant cell myocarditis.

Kaj Ekström1, Jukka Lehtonen1, Riina Kandolin1, Anne Räisänen-Sokolowski2, Kaisa Salmenkivi2, Markku Kupari1.   

Abstract

AIMS: There are no studies focusing on prognostic factors in giant cell myocarditis (GCM). We aimed to identify predictors of transplant-free survival in GCM. METHODS AND
RESULTS: We analysed the details of 46 patients with GCM (31 women, mean age 51 ± 12 years) seen at our hospital since 1991 and followed for the occurrence of cardiac death or transplantation till May 2015. The association of transplant-free survival with patient characteristics, laboratory data on admission, and myocardial histology in the 38 patients diagnosed prior to death or transplantation was examined. Altogether 26 patients died (n = 8) or underwent transplantation (n = 18) a median of 11 months following symptom onset. The 5-year estimate of transplant-free survival was 42% [95% confidence interval (CI) 35-48%]. By Cox regression analysis, the hazard ratio for death or transplantation was 0.87 (95% CI 0.75-0.99) per +5% difference in LVEF, 1.06 (95% CI 1.03-1.10) per + 1000 ng/L difference in NT-proBNP, and 4.57 (95% CI 1.63-11.28) for cardiac troponin-T above the median of 85 ng/L at presentation. The severity of necrosis and fibrosis in myocardial biopsy, graded by the consensus of two cardiac pathologists as none, mild, moderate, or severe, predicted the outcome with a hazard ratio of 7.17 (95% CI 2.29-22.40) for the presence of either necrosis or fibrosis of at least moderate extent.
CONCLUSIONS: In GCM, the probability of transplant-free survival is 42% at 5 years from symptom onset. Markers of myocyte injury and cardiac dysfunction help predict the outcome.
© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Inflammatory cardiomyopathy; Myocardial biopsy; Transplantation

Mesh:

Substances:

Year:  2016        PMID: 27407025     DOI: 10.1002/ejhf.606

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  13 in total

Review 1.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

2.  Convalescent Rehabilitation for an Elderly Patient with Giant Cell Myocarditis: Case Report.

Authors:  Hideki Arai; Satoru Matsumoto; Tomoyuki Morisawa
Journal:  Prog Rehabil Med       Date:  2018-11-01

3.  Brazilian Society of Cardiology Guideline on Myocarditis - 2022.

Authors:  Marcelo Westerlund Montera; Fabiana G Marcondes-Braga; Marcus Vinícius Simões; Lídia Ana Zytynski Moura; Fabio Fernandes; Sandrigo Mangine; Amarino Carvalho de Oliveira Júnior; Aurea Lucia Alves de Azevedo Grippa de Souza; Bárbara Maria Ianni; Carlos Eduardo Rochitte; Claudio Tinoco Mesquita; Clerio F de Azevedo Filho; Dhayn Cassi de Almeida Freitas; Dirceu Thiago Pessoa de Melo; Edimar Alcides Bocchi; Estela Suzana Kleiman Horowitz; Evandro Tinoco Mesquita; Guilherme H Oliveira; Humberto Villacorta; João Manoel Rossi Neto; João Marcos Bemfica Barbosa; José Albuquerque de Figueiredo Neto; Louise Freire Luiz; Ludhmila Abrahão Hajjar; Luis Beck-da-Silva; Luiz Antonio de Almeida Campos; Luiz Cláudio Danzmann; Marcelo Imbroise Bittencourt; Marcelo Iorio Garcia; Monica Samuel Avila; Nadine Oliveira Clausell; Nilson Araujo de Oliveira; Odilson Marcos Silvestre; Olga Ferreira de Souza; Ricardo Mourilhe-Rocha; Roberto Kalil Filho; Sadeer G Al-Kindi; Salvador Rassi; Silvia Marinho Martins Alves; Silvia Moreira Ayub Ferreira; Stéphanie Itala Rizk; Tiago Azevedo Costa Mattos; Vitor Barzilai; Wolney de Andrade Martins; Heinz-Peter Schultheiss
Journal:  Arq Bras Cardiol       Date:  2022-07       Impact factor: 2.667

Review 4.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 5.  Optimising Heart Failure Therapies in the Acute Setting.

Authors:  Mattia Arrigo; Petra Nijst; Alain Rudiger
Journal:  Card Fail Rev       Date:  2018-05

6.  Late gadolinium enhancement characteristics in giant cell myocarditis.

Authors:  Shujuan Yang; Xiuyu Chen; Jinghui Li; Yang Sun; Jialin Song; Hongyue Wang; Shihua Zhao
Journal:  ESC Heart Fail       Date:  2021-03-02

7.  Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation.

Authors:  Vinisha Garg; Weiyi Tan; Reza Ardehali; Janki Shah; Tracy Huynh; Olcay Aksoy
Journal:  ESC Heart Fail       Date:  2017-03-08

8.  Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series.

Authors:  Kaj Ekström; Anne Räisänen-Sokolowski; Jukka Lehtonen; Hanna-Kaisa Nordenswan; Mikko I Mäyränpää; Markku Kupari
Journal:  ESC Heart Fail       Date:  2020-04-28

9.  Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.

Authors:  Enrico Ammirati; Maria Frigerio; Leslie T Cooper; Paolo G Camici; Eric D Adler; Cristina Basso; David H Birnie; Michela Brambatti; Matthias G Friedrich; Karin Klingel; Jukka Lehtonen; Javid J Moslehi; Patrizia Pedrotti; Ornella E Rimoldi; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circ Heart Fail       Date:  2020-11-12       Impact factor: 8.790

10.  Giant Cell Myocarditis: Still the Deadly Giant.

Authors:  Nowell M Fine
Journal:  JACC Case Rep       Date:  2020-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.